A review of paraoxonase 1 properties and diagnostic applications

M. Kulka

Department of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776 Warszawa, Poland

Abstract

Paraoxonase 1 (PON1) is an arylesterase associated with serum high density lipoprotein particles. Its name is derived from hydrolyzing one of several organophosphate compounds, namely paraoxon. Recent studies have shown that PON1 plays a protective role in diseases associated with oxidative stress such as atherosclerosis and diabetes mellitus. Studies have demonstrated reduction-oxidative state changes involving PON1 in humans and laboratory animal models. Although there is less information about the role of this enzyme in veterinary medicine, new data suggest that PON1 might be a new oxidative stress marker in animal patients, similarly to humans.

Key words: PON1, properties, diagnostic applications

Introduction

Paraoxonases are a family of enzymes with esterolytic properties, hydrolyzing organophosphate compounds. There is evidence suggesting that some play a protective role against oxidative stress. There are several publications about enzyme coding, structure, activity and changes in concentration in mice, other laboratory animals and in humans. However there is only a small amount of information about this enzyme in other species.

PON1 synthesis and high density lipoprotein association

In mammals the PON family is coded by 3 distinct genes. Human PON genes are located on the long arm of the 7th chromosome (7q21.3-q22.1). In the mouse -- on the 6th arm, near D6Mit86 (Sorenson et al. 1995). Synthetized in liver, PON1 and PON3 can be found in plasma whereas PON2 is primary an intracellular enzyme.

PON1 (E.C. 3.1.8.1.) is associated with high density lipoprotein particles. Human HDLs are a heterogeneous group of lipoproteins which may be classified according to their increasing size: HDLc, HDLb, HDLα, HDLβ, HDL (Rosenson et al. 2011). In healthy individuals the highest PON1 serum activity, using ultracentrifugation and automated fractionation methods, was found in the HDL subfraction with density ranging from 1.175-1.185 kg/L, with a maximum activity at 1.18 kg/L. This is the HDL3 subclass (Bergmeier et al. 2004). In addition, Gugliucci et al. (2013), using different methods, confirmed PON1 activity in the smaller particles (HDLc). In their study the activity was measured in situ after native gel electrophoresis in 18 human males and 15 females in good health.
In bovine serum over 85% of paraoxonase and arylesterase activity was also measured in HDL fractions. Four classes of HDL fractions can be distinguished in Holstein Friesian and Japanese Blacks based on size. HDL-1 with 13.8 – 14.9 nm, HDL-2 with 12.0 – 14.5 nm, HDL-3 with 11.5-13.5 nm and HDL-4. HDL-4 corresponds to heavy HDL (Bauhart et al. 1993) ranging from 9.2 to 12.1 nm in which the PON1 presence was mainly detected. Less than about 5% of PON1 activity for both substrates was found in very low density lipoprotein (VLDLs) and low density lipoprotein (LDLs) fractions. In the Holstein Friesian, Japanese Blacks, Swiss Blacks and Montofon bovine breeds PON1 was identified as 43 kDa protein (Miyamoto et al. 2005, Erengin et al. 2014).

PON1 is associated with the major HDL structural Apolipoprotein A-I (Apo A-I) (Mackness et al. 1988). PON1 – Apo A-I binding occurs with high affinity and leads to increased enzyme stability. Furthermore, it also influences lactonase activity (Gaidukov et al. 2010). These facts suggest that the lipoprotein might be a physiological acceptor for PON1. In a study published by Deakin et al. (2002) the authors described adding HDL particles (containing apolipoproteins A-I and A-II) to hepatic and ovary transfected cell cultures expressing enzymatically active human PON1 (hPON1) on the external cellular membrane surface. In addition the enzyme arylesterase activity was confirmed on non-permeabilized cells by adding phenyl acetate. After HDL incubation with hepatic and ovary transfected cells for an indicated period of time, a 2-3-fold PON1 activity increase in the culture media was measured. Moreover, a significant cell-bound PON1 activity depletion was seen in the presence of HDL. This indicates a possible role of lipoproteins in PON1 detachment from the external surface of cell membranes. PON1 binding to the HDL might not be permanent. Experiments with hamster ovary and human endothelial cells demonstrated that PON1 associated with HDL could be transferred onto the external face of the plasma membrane of the cells without losing its activity (Deakin et al. 2011). Moreover, data showed that the HDL scavenger receptor class B member 1 (SR-B1) plays a crucial role in the transfer process. Downregulated expression of this receptor, due to siRNA, was correlated with decreased transfer efficiency (Deakin et al. 2011).

**PON1 substrates, polymorphism influence**

A variety of synthetic and natural substrates are hydrolyzed by PON1. Aldrige (1953) classified PON1 as an A-esterase, an enzyme hydrolyzing organophosphates and aromatic esters, while B-esterase enzymes, such as cholineoesters and serine carboxylesterases, were inhibited by paraoxon or other organophosphates.

PON1 hydrolysis oxon metabolites in most mammals (Carr et al. 2015). Experiments with PON1 knockout mice showed a dramatic sensitivity increase to diazoxon exposure, which resulted in 80% inhibition of cholineoesterase in comparison to wild type mice. Administration of higher doses was lethal to the strains without PON1 expression and had no effect on wild mice with functional PON1. PON1 catalytic efficiency differ depending on the substrate type, and are higher towards i.e. chlorpyrifos oxon and diazoxon, than its esterolytic abilities towards diazinon and paraoxon (Li et al. 2000). Its activity also differs between species, PON1 activity is higher in rabbits and rats than in cows, pig and horses (Carr et al. 2015). Another group of synthetic substrates are aromatic esters. These include phenyl acetate, 2-naphthyl acetate and thiophenyl acetate. The most common substrates used to assess PON1 activity in experiments include paraoxon and phenyl acetate.

All paraoxonases hydrolyze aromatic and long chain aliphatic lactones such as dihydrocoumarin or 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-HETE) lactones. PON1 lactonase activity might have an influence on administered drugs used during treatment. Examples include human PON1 activity on prulifloxacin or human PON3, which hydrolyzes the statin lactones lovastatin and simvastatin or diuretics such as spironolactone (Draganov et al. 2005), used in human and veterinary medicine (Schuller et al. 2011).

A natural group of PON1 substrates comprised cell membrane associated phospholipid hydperoxides (Ferretti et al. 2004), lipoprotein hydroperoxides and cholesteryl esters. Incubation of oxidized HDL with purified PON1 for 2 hours reduced lipoprotein peroxides by 19% and reduced HDL cholesterol linoleate hydperoxides by 90%. Paraoxonase activity was also shown when HDL-associated and purified PON1 were added to a hydrogen peroxide solution. After 120-minutes incubation a time-dependent reduction of H2O2 up to 25% was seen in the solution (Aviram et al. 1999B). Oxidized-LDL phospholipids and cholesteryl esters, as products of the atherosclerosis process, are physiological substrates for PON1. Thus, paraoxonase acts to protect LDLs against oxidation (Aviram et al. 1999). Inactivated HDL-associated PON or purified PON (by usage of specific inhibitors) stimulated LDL oxidation when incubated together with CuSO4 in solution.

In addition, PON1 polymorphism influences enzyme activity characteristics in humans and rabbits, where 3 phenotypes can be seen. Addition of saline stimulated a trimodal pattern first found in the Cau-
PON1 activity

Studies indicate (Aviram et al. 1998A, Aviram et al. 1998B) that PON1 might have two separate active sides for esterolytic and hydroxyperoxide activities, which differ in their mechanisms. One, with hydrolytic activity, would metabolize substrates such as esterified lipids. The other would take part in hydroperoxides reduction. It is proposed that both might play in concert in vivo, with the esterolytic side generating the preferred substrates i.e. free fatty acid hydroperoxides for further reduction by the second active side. Data presented by Karabina et al. (2005) agree with this concept, where the oxidized form of linoleic acid ester, namely p-nitrophenyl 13-hydroperoxylinooleate (pNPHPDE), was used as a substrate for PON1. The reduction paralleled hydrolysis indicating esterolytic activity requirement before the estirfied fatty acid hydroperoxide was reduced.

The PON1 hydroxyperoxide-reducing activity was not affected by the presence of chelating factors unlike esterolytic activity, which was lower in samples collected using EDTA or citrate (Karabina et al. 2005). Furthermore, modification of cysteine free sulphydryl group at the 283rd position in PON1 influenced its enzymatic activity. Inactivation of -SH by blocking it using iodoacetate caused a significant reduction in LDL oxidation inhibition, whereas minimally affected arylesterase activity. Similar effects were accomplished when using recombinant PON mutants in which the cysteine at 283rd position was changed (and in the same manner the residue of amino acid) to serine (Cys283Ser) or alanine (Cys283Ala). The amino acid replacement also led to reduced enzyme activity and PON1 mutants were unable to inhibit LDL oxidation (Aviram et al. 1998A).

Oxidation itself next to the enzyme polymorphism, cysteine residue changes, and different anticoagulant usage could also modify PON1 efficiency. There are several reports about oxidative inactivation of paraoxonase (Cao et al. 1999, Jaouad et al. 2003).

It is likely that in experimental environmental conditions PON1 activity was suppressed due to reactive oxygen species generation (Nguyen and Sok 2003). Addition of antioxidants such as vitamin E in some assays preserved the PON1 inactivation, where pyrrolidine dithiocarbamate (PDTC), a strong antioxidant, completely preserved the PON1 hydrolytic activity (Karabina et al. 2005). What is interesting a similar protection of enzyme activity was seen when 1M of glucose was used, suggesting that very high concentrations might be self-quenching. This is in contrast to an esterolytic activity loss obtained by incubation with glucose in lower (physiologically normal) and slightly elevated concentrations – respectively 5 mM and 100 mM (Karabina et al. 2005).

Although PON1 has a high affinity to HDL, when PON1 protein is transferred from serum to cell membranes it still possesses its antioxidant abilities. When culture cells with membrane bound PON1 were incubated with ox-LDL or 2,2′-azobis(2-amidinopropane)
Fig. 1. PON1 protective function against foam cell formation and plaque development in atherosclerosis. Monocytes enter an artery wall media (stimulated by M-CSF and MCP-1), where they are loaded with ox-LDL and transformed to foam cells. PON1: – inhibits the LDL oxygenation process by ROS and therefore leads to oxidized low-density lipoproteins decrease; – increases the enhancement of cholesterol efflux from macrophages. PON1 also diminishes monocyte chemoattractant protein-1 synthesis by endothelial cells thus leading to a decrease in foam cells formation. PON1 – paraoxonase 1, ROS – reactive oxygen species, MCP-1 – monocyte chemoattractant protein-1, HDL – high density protein, LDL – low density protein, ox-LDL – oxidized low-density lipoprotein, M-CSF – macrophage colony-stimulating factor (Camps et al. 2012, modified).

PON1 as a member of the acute phase proteins (APP)

PON1 is treated as a negative acute phase protein and its concentration decreases during inflammatory conditions. In humans and rabbits during acute phase response, Apo A-I levels and PON1 activities were simultaneously depleted (Van Lenten et al. 1995). It seems that under inflammatory conditions displacement of Apo A-I by the positive acute phase protein – serum amyloid A (SAA) in HDL might occurred, thus leading to a decrease in PON1 activity. However, in mice with acute infection a decrease in PON1 and platelet activating factor acetylhydrolase (PAF-AH) activities was concomitant with unchanged Apo A-I levels (Van Lenten et al. 2001).

Acute phase response induced by endotoxin, lipopolysaccharide (LPS), caused a decrease in PON1 serum activity (over 60%) within 48 hours in Syrian Hamsters and initiated a rapid decrease in PON1 mRNA concentrations persisting for at least 48 hours in hamster hepatic cell cultures. Moreover, it was observed that mediators such as Tumor Necrosis Factor (TNF) and IL-1 diminished PON1 activity in a similar manner (Feingold et al. 1998).

Clinical studies involving individuals confirmed previous in vitro observations with LPS administration. PON1 plays in concert with other APPs during the inflammatory process.

PON1 negative acute phase response changes with concomitant elevation of APP positive were measured in severe conditions in human sepsis and animal parasitic infections. People in critical states during infection had decreased PON1 activity and a significant negative correlation with C reactive protein (CRP) (Novak et al. 2010) which is a well studied positive acute phase protein (Gewurz et al. 1982, Jain et al. 2011). Similar changes can be seen in canine heartworm disease. Dogs infected with Dirofilaria immitis (amicrofilaremic, microfilaremic) had reduced PON1 activity, decreased albumin concentration (APP negative) and a negative correlation with CRP concentrations in serum. However, there was no difference in negative acute phase protein levels between asymptomatic or symptomatic (cough, lung crackles, ascites, cachexia, exercise intolerance) antigen positive dogs, suggesting that CPR is a more universal marker in dirofilariosis (Mendez et al. 2014).
PON1 changes in different diseases

Changes in the redox state can be encountered in many diseases e.g. atherosclerosis, diabetes mellitus, obesity, chronic liver inflammation. Similar changes also occur in physiological processes, such as the periparturient state. PON1 involvement is being intensively studied to assess its function and potential applications as an additional marker in diagnostics and in monitoring patient health.

Several experiments have shown PON1 to have a protective function in atherosclerosis (Mackness et al. 2004, Camps et al. 2012). In this process modifications of lipoproteins, such as oxidation, might lead to foam cell formation crucial for lipid plaque development (Fig. 1). Foam cells are created by rapid receptor uptake of oxidized LDL (ox-LDL) and depot in macrophages. In vitro uptake of unchanged LDL particles by those cells is very slow. In mice with PON1 knockout, macrophages have shown increased oxidative stress and reduction of cellular glutathione concentrations (an antioxidant) (Rozenberg et al. 2003), thus leading to LDL oxidation and resulting in macrophage foam cell formation (Aviram and Rosenblat 2004). In addition, mice lacking PON1/apo E proteins exhibited more severe atherosclerotic changes as their LDL particles were more sensitive to oxidation (Shih et al. 2000). Results in rodent models were similar to those in human patients. People with coronary heart disease determined by angiographic evaluation had an increase in LDL-cholesterol concentrations (133±45 mg/dl) in comparison to healthy patients (121±27 mg/dl). Also a trend in PON1 activity decrease was observed in patients with heart disease 41.6±26.8 U/l (control 52.3±30.5 U/l) (Azarisiz et al. 2003).

PON1 is also responsible of inhibiting monocyte chemoattractant protein-1 (MCP-1) produced by endothelial cells in atherosclerosis (Fig. 1). The up-regulation of MCP-1 secretion by ox-LDL is one of the primary events leading to plaque formation (Lusis 2000). Purified PON1 or HDL containing PON1 inhibit the ox-LDL stimulated MCP-1 production. In contrast, avian HDL (which lacks PON1) do not suppress this process (Mackness et al. 2004). It has been shown that paraoxonase, due to its activity, prevents LDL-derivated oxidized phospholipid formation (ie. 1-palmitoyl-2(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine (POVPC) and 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine (PGPC)). Both stimulate adhesion of monocytes to the endothelium and the production of MCP-1 (Navab et al. 2001). Another anti-atherosclerotic role of PON1 might be the formation of lysophosphatidylcholine (LPC) in macrophages (Rosenblat et al. 2005) which enhances HDL binding to macrophages and therefore enhances cholesterol efflux from cells (Fig. 1).

Significant changes in PON1 can be seen in patients with diabetes mellitus (DM) (type 1 and type 2), where its activity is reduced in contrast to negatively correlated serum SAA levels (Juretic et al. 2006, Kappelle et al. 2011). A PON1 activity depletion was observed in DM type 1 patients with a higher HDL lipid hydroperoxide concentration and was correlated with elevated oxid-LDL levels in DM type 2 subjects (Ferretti et al. 2004, Tsuzura et al. 2004). This data might suggest lower ability of small density HDL₃ (fraction with highest PON1 activity) to protect lipoproteins against oxidation in comparison to healthy individuals (Nodecourt et al. 2005).

In diabetes a significant amount of PON1 is dissociated from HDL in serum to the lipoprotein-deficient serum fraction (LPDS). The dissociation of PON1 in diabetic patients could be a result of a partially peroxidized HDL lipoprotein or/and reduced Apo A-I levels. Also PON1 antioxidant activity in the LPDS fraction is reduced when incubated in induced lipid peroxidation conditions. This is in comparison to PON1-HDL bound abilities and leads to a conclusion that only PON1 bound to HDL is able to play a protective role in diabetes against increased oxidative stress (Rosenblat et al. 2005).

PON1 changes in transition period

Some data has shown changes in PON1 activity around the periparturient period predisposed for reactive oxygen species (ROS) formation. Pregnancy and mid lactation period of dairy cows have a great influence on sucrose and lipid metabolic changes. Serum activity of PON1 towards paraoxon was decreased in non-pregnant Holstein-Friesian cows during 8-12 weeks postpartum (Antonicc-Svetina et al. 2011). During this time large adipose mobilization takes place, and concentration of non-esterified fatty acids (NEFAs) and reactive oxygen species in the blood stream is increased (Bionaz et al. 2007). Thus, leading to oxidative stress, enhanced peroxidation and acute phase response (Steinberg 1997, Khovidhunkit et al. 2000), lowering PON1 activity and its’ hydrolysis of lipid peroxides. Additionally, around the transition period a negative energy balance could be a factor increasing ROS concentration (Roche et al. 2000, Antonicc-Svetina et al. 2011). PON1, through its activity, protects conversion of free cholesterol to cholesterol esters by lecithin cholesterol acyltransferase (LCAT). This conversion via LCAT leads to HDL core formation (Gan et al. 1991). Serum PON1 activity significantly decreases shortly after parturition in
comparison to non-pregnant cows (Turk et al. 2004) and its depletion is seen in dairy cow fatty liver syndrome (Farid et al. 2013).

However, animals with an optimal oxidative state, good Edmonson’s Body Condition Score (Edmonson et al. 1989) and optimal nutrioning still have decreased serum PON1 activity in postpartum period. The PON1 depletion seems to be a universal pattern seen in different breeds (Kulka et al. 2014, Kulka et al. 2016).

Cooperation with other antioxidant enzymes (markers)

In DM type 2, a diminished PON1 activity was seen simultaneously to superoxide dismutase (SOD) decrease and catalase (CAT) increase (Sözmen et al. 2001). Moreover, there was a positive correlation between CAT/SOD, CAT/PON1 ratios and glycated hemoglobin concentration. In light of those results PON1 might be used as a marker in control management of diabetes. Moreover, it might possible that paraoxonase plays in concert with other antioxidant systems in vivo, gaining its protection against oxidative thus preserving its antioxidant abilities. Increased PON1 levels, by enhancing LPC production, lead to extracellular expression of SOD in monocyte-macrophages as an antioxidant effect in atherosclerosis, which also might suggest a cooperation of antioxidant systems (Rosenblat et al. 2006).

PON1 plays an important role in protection against oxidative stress present in many diseases. In the acute phase response it acts like negative acute phase protein, with decreased activity. Well studied in human medicine, PON1 assessment gives useful information about many aspects of diseases such as atherosclerosis or DM. PON1 is becoming an important diagnostic tool of redox state disruption in companion and farm animals. However, future studies concerning new implications in veterinary medicine are still to be made.

Acknowledgments

The study was supported by the NCN grant No. N.N. 308562840.

References


A review of paraoxonase 1 properties and diagnostic applications


